1363281-51-9

Basic information

• Product Name: 5-(4-fluorobenzoyl)-2-[(4-fluorophenoxy)methyl]-4,5,6,7-tetrahydro-oxazolo[5,4-c]pyridine
• CAS NO: 1363281-51-9
• Molecular Weight: 370.355
• Mol File: 1363281-51-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-(4-fluorobenzoyl)-2-[(4-fluorophenoxy)methyl]-4,5,6,7-tetrahydro-oxazolo[5,4-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-fluorobenzoyl)-2-[(4-fluorophenoxy)methyl]-4,5,6,7-tetrahydro-oxazolo[5,4-c]pyridine(1363281-51-9)
• EPA Substance Registry System: 5-(4-fluorobenzoyl)-2-[(4-fluorophenoxy)methyl]-4,5,6,7-tetrahydro-oxazolo[5,4-c]pyridine(1363281-51-9)

Safety Data

• Hazardous Substances Data: 1363281-51-9(Hazardous Substances Data)

Upstream product

• 1363281-27-9 (4-fluorophenyl)-[2-(phenoxymethyl)-6,7-dihydro-4H-oxazolo[5,4-c]pyridin-5-yl]methanone 
• 371-41-5 4-Fluorophenol 
• 1363287-54-0 {5-[(4-fluorophenyl)carbonyl]-4,5,6,7-tetrahydro[1,3]oxazolo[5,4-c]pyridin-2-yl}methanol 

Relevant articles and documents

Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound

This Letter describes the progress and challenges in the continued optimization of the mGlu5 positive allosteric modulator (PAM) clinical candidate VU0490551/JNJ-46778212. While many analogs addressed key areas for improvement, no one compound possessed the amalgamation of improvements needed within the (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanone scaffold to advance as a back-up clinical candidate. However, many analogs displayed excellent solubility and physiochemical properties, and were active in the amphetamine-induced hyperlocomotion (AHL) model. Moreover, the SAR was robust for this series of PAMs, and both polar and hydrogen-bond donors were found to be tolerated, leading to analogs with overall attractive profiles and good ligand efficiencies. Graphical abstract